Rani Therapeutics Holdings, Inc.
RANI
$0.6244
$0.075813.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.98% | -12.92% | -6.28% | -15.19% | -11.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.12% | -13.18% | -8.65% | -33.92% | -31.54% |
| Operating Income | 16.12% | 14.40% | 16.30% | 33.92% | 31.54% |
| Income Before Tax | 15.99% | 13.81% | -11.86% | 30.60% | 28.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.99% | 13.81% | -11.86% | 30.60% | 28.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -30.87% | -24.97% | -2.62% | -34.99% | -29.96% |
| Net Income | 1.66% | 2.93% | -26.05% | 26.25% | 26.85% |
| EBIT | 16.12% | 14.40% | 16.30% | 33.92% | 31.54% |
| EBITDA | 16.33% | 14.68% | 16.88% | 34.57% | 32.23% |
| EPS Basic | 29.17% | 24.43% | 0.15% | 34.65% | 29.58% |
| Normalized Basic EPS | 0.44% | 0.27% | 68.27% | 23.21% | 24.97% |
| EPS Diluted | 29.17% | 24.43% | 0.15% | 34.65% | 29.58% |
| Normalized Diluted EPS | 0.44% | 0.27% | 68.27% | 23.21% | 24.97% |
| Average Basic Shares Outstanding | 38.82% | 28.45% | 26.23% | 12.85% | 3.86% |
| Average Diluted Shares Outstanding | 38.82% | 28.45% | 26.23% | 12.85% | 3.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |